We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$150M
AUM Growth
-$14.4M
Cap. Flow
-$5.61M
Cap. Flow %
-3.74%
Top 10 Hldgs %
87.14%
Holding
55
New
1
Increased
10
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
EQM
EQM Midstream Partners, LP
EQM
+$1.8M
2
KALV
KalVista Pharmaceuticals
KALV
+$485K
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$415K
4
MYGN icon
Myriad Genetics
MYGN
+$291K
5
CELG
Celgene Corp
CELG
+$188K

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$7.78M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$402K
3
VCYT icon
Veracyte
VCYT
+$399K
4
NKTR icon
Nektar Therapeutics
NKTR
+$338K
5
APLS
Apellis Pharmaceuticals
APLS
+$203K

Sector Composition

Rank Sector Weight
1 Healthcare 96.12%
2 Energy 2.68%
3 Consumer Discretionary 0.06%
4 Materials 0.04%
5 Consumer Staples 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
26
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$551K 0.37%
8,300
– –
ODT
27
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$521K 0.35%
20,000
– –
VYGR icon
28
Voyager Therapeutics
VYGR
$187M
$516K 0.34%
30,000
– –
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.32B
$504K 0.34%
14,000
+4,000
+40% +$121K
PXD
30
DELISTED
Pioneer Natural Resource Co.
PXD
$478K 0.32%
3,800
– –
IMGN
31
DELISTED
Immunogen Inc
IMGN
$436K 0.29%
180,000
– –
XNCR icon
32
Xencor
XNCR
$1.4B
$415K 0.28%
12,300
– –
VCYT icon
33
Veracyte
VCYT
$4.65B
$378K 0.25%
15,767
-15,000
-49% -$399K
SLNO
34
DELISTED
Soleno Therapeutics
SLNO
$361K 0.24%
16,040
– –
KALV
35
DELISTED
KalVista Pharmaceuticals
KALV
$348K 0.23%
+30,000
New +$485K
XBIT icon
36
XBiotech
XBIT
$68.9M
$314K 0.21%
30,000
+20,000
+200% +$163K
FOLD
37
DELISTED
Amicus Therapeutics
FOLD
$305K 0.2%
38,000
– –
SIEN
38
DELISTED
Sientra, Inc.
SIEN
$259K 0.17%
4,000
– –
CLR
39
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$246K 0.16%
8,000
– –
LXRX icon
40
Lexicon Pharmaceuticals
LXRX
$1.03B
$241K 0.16%
80,000
– –
MREO
41
Mereo BioPharma
MREO
$49M
$231K 0.15%
77,570
+30,000
+63% +$90.7K
OVV icon
42
Ovintiv
OVV
$16.5B
$228K 0.15%
9,910
+410
+4% +$9.39K
CYTK icon
43
Cytokinetics
CYTK
$10.9B
$114K 0.08%
10,000
– –
WKHS icon
44
Workhorse Group
WKHS
$30.1M
$88K 0.06%
8
– –
TGTX icon
45
TG Therapeutics
TGTX
$8.4B
$84K 0.06%
15,000
– –
CFRX
46
DELISTED
ContraFect Corporation
CFRX
$81K 0.05%
284
-16
-5% -$5.38K
LTHM
47
DELISTED
Livent Corporation
LTHM
$67K 0.04%
10,000
– –
YTEN
48
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$62K 0.04%
129
– –
BCRX icon
49
BioCryst Pharmaceuticals
BCRX
$2.34B
$57K 0.04%
20,000
– –
GNMX
50
DELISTED
Aevi Genomic Medicine Inc
GNMX
$19K 0.01%
128,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Birchview Capital held 55 positions worth $150M, down 8.7% from $164M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Birchview Capital withdrew a net $5.61M in Q3 2019, closing 5 positions and reducing 3 holdings. Its most notable exit was Array Biopharma Inc, an estimated $7.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Discretionary.

Against the trend, Birchview Capital opened a new position in KalVista Pharmaceuticals worth $348K.

  • Birchview Capital's largest Q3 2019 buy was KalVista Pharmaceuticals: 30,000 shares worth $348K.
  • Birchview Capital added most to EQM Midstream Partners, LP in Q3 2019, an estimated $1.8M increase.
  • Birchview Capital's biggest Q3 2019 reduction was Veracyte, cutting an estimated $399K.
  • Birchview Capital fully exited Array Biopharma Inc in Q3 2019, selling an estimated $7.78M.
  • Birchview Capital's ten largest holdings make up 87% of its $150M portfolio in Q3 2019.
  • Birchview Capital opened 1 new position and closed 5 in Q3 2019.
  • Birchview Capital's portfolio value fell 8.7% quarter-over-quarter to $150M.

Based on Birchview Capital's 13F filing for Q3 2019, filed 12 Nov 2019.